Structural Conservation of Ligand Binding Reveals a Bile Acid-like Signaling Pathway in Nematodes*


From the †Laboratory of Structural Sciences and ‡Laboratory of Structural Biology and Biochemistry, Van Andel Research Institute, Grand Rapids, Michigan 49503, the Departments of §Pharmacology and ‖Molecular Biology and ‡‡Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390, the †Department of Microbiology, Immunology, and Tropical Medicine, George Washington University Medical Center, Washington, D. C. 20037, and the §∗∗VARI-SIMM Center, Center for Structure and Function of Drug Targets, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

Background: Nematode DAF-12s have species-specific ligand responses.

Results: Structures of a hookworm DAF-12 complexed with two different agonists are determined.

Conclusion: Bile acid-like signaling pathways have been conserved in mammals and nematodes.

Significance: Structural understanding of the hookworm DAF-12 activation is instrumental in treating nematode parasitism and points to the basis for evolution of a novel gut parasite hormone signaling pathway.

Bile acid-like molecules named dafachronic acids (DAs) control the dauer formation program in Caenorhabditis elegans through the nuclear receptor DAF-12. This mechanism is conserved in parasitic nematodes to regulate their dauer-like infective larval stage, and as such, the DAF-12 ligand binding domain has been identified as an important therapeutic target in human parasitic hookworm species that infect more than 600 million people worldwide. Here, we report two x-ray crystal structures of the hookworm Ancylostoma ceylanicum DAF-12 ligand binding domain in complex with DA and cholestenoic acid (a bile acid-like metabolite), respectively. Structure analysis and functional studies reveal key residues responsible for species-specific ligand responses of DAF-12. Furthermore, DA binds to DAF-12 mechanistically and is structurally similar to bile acids binding to the mammalian bile acid receptor farnesoid X receptor. Activation of DAF-12 by cholestenolic acid and the cholestenoic acid complex structure suggest that bile acid-like signaling pathways have been conserved in nematodes and mammals. Together, these results reveal the molecular mechanism for the interplay between parasite and host, provide a structural framework for DAF-12 as a promising target in treating nematode parasitism, and provide insight into the evolution of gut parasite hormone-signaling pathways.

DAs are a group of bile acid-like steroid hormones that were first identified as endogenous ligands for DAF-12 in Caenorhabditis elegans (1). The position of the double bond on the steroidal rings discriminates Δ4- and Δ7-dafachronic acids that both are synthesized de novo from cholesterol through several steps catalyzed by P450 enzymes, including DAF-36 and DAF-9 (2). DAF-9 catalyzes the last step of DA production by forming hydroxyl groups on the side acyl chain of its 3-keto substrates. It has been proposed that DAF-9 is the worm ortholog of mammalian CYP27A (1), a cytochrome P450 enzyme that catalyzes consecutive hydroxylations of substrate and acts at the late stage of bile acid production (3). DAF-36 is postulated to work at the earlier step of Δ7-DA production as a Rieske-like oxygenase, followed by the potential reductases and dehydrogenases to produce DA precursors (2, 4).

DAs control the dauer formation program in C. elegans through the nuclear receptor DAF-12 (1, 5). The dauer formation is an alternative developmental strategy that is adopted by the worms to tackle harsh environmental conditions. During dauer diapause, worms undergo significant changes in their morphology, physiology, metabolism, and behavior in comparison with the third larvae stage (L3) of their normal reproductive development (6, 7). The dauer formation program is transcriptionally regulated by the presence of DAs and their binding to the receptor DAF-12. In the absence of DAs, DAF-12 occupies the response elements within its promoters, recruits the corepressor DIN-1 to silence the expression of reproductive genes, and thus promotes entry into the dauer stage (8). In the presence of DAs, DAF-12 dissociates from corepressors and binds coactivators to activate a battery of genes that favor the reproductive growth and repress the dauer formation. The production of DAs is determined by DAF-9, which itself is under

* This work was supported, in whole or in part, by National Institutes of Health Grants DK071662, DK066202, and HL089301 (to H. E. X.) and DK62434 (to D. J. M.). This work was also supported by the Jay and Betty Van Andel Foundation, Howard Hughes Medical Institute (to D. J. M.), and the Robert A. Welch Foundation Grants I-1275 (to D. J. M.) and I-1558 (to S. A. K.).

This article contains supplemental Tables S1 and S2 and Figs. S1–S6. The atomic coordinates and structure factors (codes 3UPO and 3UP3) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

1 Present address: Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114.

2 To whom correspondence should be addressed. E-mail: eric.xu@vai.org.

This is an open access article under the CC BY license.

The abbreviations used are: DA, dafachronic acid; LBD, ligand binding domain; r.m.s.d., root mean square deviation; FXR, farnesoid X receptor; LXR, liver X receptor; 6ECDCA, 6α-ethyl-chenodeoxycholic acid; LCA, lithocholic acid.
the control of upstream signaling pathways (7). As such, signaling circuits initiated by responses to environmental changes converge at the DA production and DAF-12 activity to control the developmental choice (7).

Nematode parasitism is a threat to human health care and economic development (9). The hookworm species (including Ancylostoma ceylanicum and Necator americanus in this study) infect more than 600 million people worldwide (10). Parasitic nematodes are believed to have evolved from free-living ancestors, and their third larval stage (infective, iL3) is morphologically similar to the dauer stage in C. elegans (11–13). Recent studies revealed the importance of the DAF-12 signaling in regulation of the iL3 in parasitic nematodes (14, 15). DAF-12 homologs in the threadworm Strongyloides stercoralis (Sst-DAF-12) and the hookworms A. ceylanicum (AceDAF-12, pan-specific), Ancylostoma caninum (AcaDAF-12, dog-specific), and N. americanus (NamDAF-12, specific to humans) have been cloned, and sequence analysis reveals a significant level of identity with C. elegans DAF-12 (CelDAF-12) (14). The LBDs of hookworm DAF-12s share 46% identity to the SsrDAF-12 LBD and 58% identity to the CelDAF-12 LBD (see Fig. 1A). The parasitic DAF-12s can be activated by DAs in in vitro assays. Moreover, DA treatment partially caused their iL3 larvae to start feeding. (25S)-Δ7-DA effectively blocked iL3 formation in S. stercoralis by forcing the iL3 larvae to prematurely molt into development-defective larvae, thus markedly reducing the pathogenic iL3 population. These findings suggested that DAF-12 is a conserved nuclear receptor across nematode species and established DAF-12 as a potential drug target to treat nematode parasitism (14). Orthologs of the DA synthesis enzyme DAF-9 could not be identified in hookworms and threadworms (14). In addition, presumably because of the lack of a functional DAF-9, hookworm iL3 larvae could not be rescued in the presence of the DA precursor lathosterone, whereas C. elegans dauer larvae (daf-16 mutants) could be rescued (2, 14). Currently it remains unknown how DAF-12 of parasitic nematodes is activated physiologically.

The crystal structure of the threadworm Sst-DAF-12 LBD has been solved and revealed the general molecular basis for receptor activation in the presence of DAs. However, mutational studies indicated species-specific pharmacological responses (14). To further study the structural biology of DAF-12 and to elucidate the structural basis for species-specific ligand binding, we solved the crystal structure of the hookworm AceDAF-12 LBD bound to (25S)-Δ7-DA. By comparing the two parasitic DAF-12 LBD structures, we identified the structural elements responsible for the species-specific ligand responses. Furthermore, we compared the AceDAF-12 LBD with mammalian nuclear receptor LBDs. Interestingly, DAF-12 shares specific structural features with the mammalian bile acid receptor FXR, especially with respect to the orientation of the bound ligand. This result suggests that their ligand binding mechanism and bile acid-like signaling pathways have been conserved across evolution. Finally we showed that bile acid (like) metabolites in mammals can activate nematode DAF-12s and presented the crystal structure of the hookworm AceDAF-12 LBD bound to (25S)-cholestenoic acid. Together, our work reveals the structural mechanism of ligand recognition by DAF-12 and points to the basis for evolution of a novel gut parasite hormone signaling pathway.

**EXPERIMENTAL PROCEDURES**

**Plasmids and Reagents**—The mutants used for crystallization, AlphaScreen, or cotransfection assays were created by site-directed mutagenesis using the QuikChange method (Stratagene) and verified by sequencing. DAs and cholestenoic acids were synthesized as described elsewhere (1, 16).

**Protein Preparation and Crystallization**—DAF-12s were cloned as described and inserted as His6-GST fusions into an engineered pET24 vector (14). For biochemical assays, the proteins were expressed in BL21 (DE3) cells and purified by glutathione-Sepharose chromatography, and their ligand binding activity was tested in AlphaScreen luminescence proximity assays (17). For crystallography, AceDAF-12 LBD was expressed in BL21 (DE3) cells as His6-SUMO fusion. The protein was first purified by nickel-nitrioltriacetic acid chromatography. The SUMO tag was removed with Ulp1 protease (18), and the untagged monomeric LBD was purified by size exclusion chromatography.

The purified AceDAF-12 LBD protein was mixed with coactivator peptide (SRC2-3) and ligands ((25S)-Δ7-DA or (25S)-cholestenoic acid) for crystallization. The molar ratio of these components was 1 (DAF-12 protein):1.5 (peptide):5 (ligand). (25S)-Δ7-DA crystals were grown at 20 °C in sitting drops containing 1.0 μl of the protein solution (8.0 mg/ml) and 1.0 μl of the well solution containing 0.1 M sodium acetate, pH 5.1, 0.2 M ammonium acetate, 26% w/v PEG2000. (25S)-Cholestenoic crystals were grown at 20 °C in sitting drops containing 1.0 μl of the protein solution (7.3 mg/ml) and 1.0 μl of the well solution containing 0.2 M di-ammonium tartrate, 20% w/v PEG3350. In general, crystals appeared within 2 days and grew to the final size in about 1 week, at which time they were flash-frozen and stored in liquid nitrogen.

**Data Collection, Structure Determination, Refinement, and Superposition**—The diffraction data were collected with a MAR225 CCD detector at 21-ID beamline at the Advanced Photon Source at Argonne National Laboratory (Argonne, IL). The observed reflections were reduced, merged, and scaled with DENZO and SCALEPACK in the HKL2000 package. The structure was determined with the PHASER program by molecular replacement using the crystal structure of Sst-DAF-12 as a model. Manual model building was carried out with the programs O (19) and QUANTA (Accelrys, Inc.), and the structure was refined with crystallography NMR software and CCP4 programs refmac5. Protein model superposition was performed using O. The data collection and structure determination statistics are summarized in Table 1.

**AlphaScreen Assays**—The binding of the cofactor motifs to DAF-12 LBDs was determined by AlphaScreen luminescence proximity assays as described (14, 17, 20). Reaction mixtures consisted of 50 nM His6-GST fusion proteins, 20 nM biotinylated peptides, ligands (1 μM (25S)-Δ4- or (25S)-Δ7-DA or 10 μM (25S)- or (25R)-cholestenoic acid) or no ligand, 5 μg/ml nickel chelate-coated acceptor beads (PerkinElmer Life Sciences), and 5 μg/ml streptavidin-coated donor beads (PerkinElmer Life Sciences) in a buffer containing 50 mM...
Hookworm DAF-12 Structures

TABLE 1
Data collection and refinement statistics

<table>
<thead>
<tr>
<th></th>
<th>AceDAF-12/(25S)-Δ7-DA</th>
<th>AceDAF-12/(25S)-cholestenoic acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDB code</td>
<td>3UP0</td>
<td>3UP3</td>
</tr>
<tr>
<td>Data collection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Space group</td>
<td>P21</td>
<td>P21</td>
</tr>
<tr>
<td>Resolution</td>
<td>30 to 1.60 Å</td>
<td>30 to 1.25 Å</td>
</tr>
<tr>
<td>Cell parameters a, b, and c</td>
<td>48.0, 85.1, 66.1 Å</td>
<td>34.5, 85.3, 46.3 Å</td>
</tr>
<tr>
<td>β</td>
<td>107.1°</td>
<td>106.9°</td>
</tr>
<tr>
<td>Unique reflections</td>
<td>67,306 (6745)</td>
<td>64,400 (4055)</td>
</tr>
<tr>
<td>R_m</td>
<td>0.102 (0.609)</td>
<td>0.048 (0.400)</td>
</tr>
<tr>
<td>I/σ</td>
<td>22.0 (2.7)</td>
<td>35.2 (3.5)</td>
</tr>
<tr>
<td>Completeness</td>
<td>100% (100%)</td>
<td>91.2% (57.3%)</td>
</tr>
<tr>
<td>Redundancy</td>
<td>7.6 (7.5)</td>
<td>4.2 (3.8)</td>
</tr>
<tr>
<td>Structure determination and refinement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resolution</td>
<td>30 to 1.60 Å</td>
<td>30 to 1.25 Å</td>
</tr>
<tr>
<td>No. of reflections</td>
<td>57,044</td>
<td>59,703</td>
</tr>
<tr>
<td>No. of residues</td>
<td>590</td>
<td>261</td>
</tr>
<tr>
<td>No. of solvent molecules</td>
<td>543</td>
<td>224</td>
</tr>
<tr>
<td>No. of non-H atoms</td>
<td>4697</td>
<td>2326</td>
</tr>
<tr>
<td>R_work</td>
<td>18.34%</td>
<td>16.61%</td>
</tr>
<tr>
<td>R_ref</td>
<td>20.19%</td>
<td>18.04%</td>
</tr>
<tr>
<td>r.m.s.d. bonds</td>
<td>0.013 Å</td>
<td>0.013 Å</td>
</tr>
<tr>
<td>r.m.s.d. angles</td>
<td>1.363°</td>
<td>1.522°</td>
</tr>
<tr>
<td>Average B factor</td>
<td>14.402 Å²</td>
<td>9.299 Å²</td>
</tr>
</tbody>
</table>

RESULTS

Crystallization of the A. ceylanicum DAF-12 LBD Complexed with (25S)-Δ7-DA—Sequence analysis revealed that hookworm DAF-12 LBDs are nearly 100% identical among A. ceylanicum, N. americanus, and A. caninum species but only share 46% sequence identity to the threadworm SstDAF-12 LBD (Fig. 1A). In this study, we chose the Ace/NamDAF-12 LBD (the A. ceylanicum and N. americanus LBDs are identical) for crystallization, because A. ceylanicum and N. americanus are the major cause for human hookworm infections (10). Reportedly, crystallization of a number of nuclear receptor LBD complexes requires the inclusion of LXXL motifs (14, 17, 20). By doing so, the LXXL motifs stabilize the AF2 helix (H12) that is otherwise relatively mobile and thus promote nuclear receptor crystal packing. Because the LXXL-containing cofactors in C. elegans remain uncharacterized, we tested 12 mammalian LXXL-containing coactivator peptides and LXXXIIIXXXX(L/I)-containing corepressor peptides (see supplemental Table S1) for ligand-dependent AceDAF-12 LBD interactions in AlphaScreen assays. As shown in Fig. 1B, AceDAF-12 showed strong binding to SRC1–4 and SRC2–3, in comparison with weaker binding to SRC1–2 and PGC1α-1 and in the presence of DAs. DAF-12 from A. caninum, N. americanus, and S. stercoralis species had similar binding patterns in the assays (supplemental Fig. S1). Accordingly, SRC1–4 and SRC2–3 peptides were included in our crystallization trials along with (25S)-Δ7-DA.

Initial attempts to express the AceDAF-12 LBD yielded low amounts of soluble protein. Because cysteine mutation is a widely used strategy to solubilize recombinant proteins by preventing the random formation of disulfide bonds that cause protein precipitation (23), we mutated the four cysteines in the AceDAF-12 LBD to serines (Cys → Ser). Evaluation of the predicted positions of these cysteine residues based on the SstDAF-12 LBD structure suggested that these cysteines are distributed in loops or kinks, away from the functional cores (Fig. 1C). Mutation of four cysteines (4CS, C553S/C607S/C625S/ C680S) markedly increased AceDAF-12 LBD solubility and yielded 3–4 mg of protein from 6 liters of culture, making crystallization possible. To facilitate crystallization, we also mutated a number of nonconserved lysines in AceDAF-12 corresponding to surface amino acids in SstDAF-12 that might affect crystal packing because of the flexibility of the lysine side chain (Lys → Xaa) (Fig. 1C). As a result, several AceDAF-12 LBD mutants were made and used for crystallization. They were named AceDAF-12 LBD 4CS-3KX (K475A/K505R/K550G plus 4CS), 4CS-4KX1 (K475A/K505R/K550G/K642Q plus 4CS), 4CS-4KX2 (K463Q/K475A/K505R/K550G plus 4CS), and 4CS-5KX (K475A/K505R/K550G/K580N/K642Q plus 4CS). 4CS-4KX1 yielded acceptable crystals for structure determination. Interestingly, these crystals could only be grown by using the sitting drop but not hanging drop technique under the same precipitation conditions. Notably, as predicted from the SstDAF-12 LBD structure, Cys → Ser and Lys → Xaa mutations did not affect the ability of AceDAF-12 to bind cofactor peptides in a DA-dependent manner in AlphaScreen assays (Fig. 1D).
Structure Analysis of the AceDAF-12 LBD Complexed with (25S)-H9004-7-DA—The AceDAF-12 LBD/(25S)-H9004-7-DA structure was solved at a resolution of 1.60 Å, with two complexes, herein referred to as a and b, each in noncrystallographic symmetric unit. The overall architecture of both complexes is similar to other nuclear receptor LBDs, appearing as a well wrapped three layer helical sandwich made of 13 helices and 3 strands (Fig. 2A shows complex a). The ligand is surrounded by the same sets of amino acids in both complexes as seen in the structure of the threadworm SstDAF-12 LBD (14), consisting of hydrophobic amino acids surrounding the steroid skeleton and polar amino acids interacting with both ends of the ligand (Fig. 2B and supplemental Fig. S2). Superposition of a and b complexes indicates that they have a root mean square deviation (r.m.s.d.) of 0.563 Å. The major difference between the two complexes is the conformation of \( \beta \)-turns, which causes the ligand ((25S)-H9004-7-DA) to take a slightly different conformation in the ligand binding pocket because of the differential space arrangements of the ligand in the two complexes. The C3-keto group of H9004-7-DA forms an H-bond with Gln-571 in b (3.1 Å), which is absent in a. Instead, H9004-7-DA forms a single H-bond with a nearby water molecule (2.8 Å) in a, an interaction also witnessed in b (3.3 Å) (Fig. 2C). There is also a difference in the length of H-bonds formed with the C27-carboxyl group of H9004-7-DA in the two complexes (Fig. 2D). This finding suggests that AceDAF-12 LBD may bind \( \Delta^7 \)-DA in two slightly different modes, which are interconvertible in solution.

FIGURE 1. Strategy for crystallization of the AceDAF-12 LBD. A, sequence identity of DAF-12 homologs from parasitic nematodes. Numbers refer to the amino acid position in the LBD of each receptor. Amino acid 449 is alanine in AceDAF-12 and NamDAF-12 but is valine in AcaDAF-12. B, AlphaScreen assays to search for AceDAF-12-interacting peptides. 1 \( \mu \)M (25S)-DA is used. C, alignment of secondary structural elements of the AceDAF-12 LBD is based on the crystal structure of the SstDAF-12 LBD. H, \( \alpha \)-helix; \( \beta \)-strand. Cysteines in AceDAF-12 that were mutated to serines are boxed. Lysines in AceDAF-12 that were mutated to the corresponding amino acids in SstDAF-12 are highlighted in black. Numbers refer to the lysine position in the AceDAF-12 LBD. D, ligand binding function of AceDAF-12 mutants for crystallization is examined in AlphaScreen assays. 4CS, C553S/C607S/C625S/C661S; 4CS-3KX, K475A/K505R/K550G plus 4CS; 4CS-4KX1, K475A/K505R/K550G/K642Q plus 4CS; 4CS-4KX2, K463Q/K475A/K505R/K550G plus 4CS; 4CS-5KX, K475A/K505R/K550G/K580N/K642Q plus 4CS. 1 \( \mu \)M (25S)-DA is used. 4CS-4KX1 was successful for subsequent crystallization.
FIGURE 2. Structure analysis of the AceDAF-12 LBD. A, ribbon model reveals the overall architecture of the AceDAF-12 LBD chain α (green) complexed with (2S)-Δ7-DA (white) and the coactivator peptide SRC2-3 (brown). The AF-2 helix is highlighted in magenta. Mutated cysteines are in red and mutated lysines in orange. B, electron density map of the AceDAF-12 α chain ligand binding pocket bound to (2S)-Δ7-DA. The surrounding amino acids are highlighted in yellow. See supplemental Fig. S2 for the electron density map of complex b. C, H-bonding of AceDAF-12 amino acids and water involved in binding the C3-keto group of (2S)-Δ7-DA. Arg-574 (red box) serves as the H-bonding network hub. D, H-bonding of AceDAF-12 amino acids and water to the C27-carboxyl group of (2S)-Δ7-DA. Arg-536 (red box) can compensate Arg-532 for interacting with the ligand. H-bonds are illustrated by white dashed lines with bond lengths noted in Å. The first number in parentheses indicates the bond length in complex a and the second number indicates bond length in complex b. E, amino acids involved in binding the coactivator peptide SRC2-3 (salmon) are labeled. F and G, mutation of the labeled amino acids (E) in AceDAF-12 (F) or corresponding amino acids in CelDAF-12 (G) disrupts the binding to SRC2-3 LXXL coactivator motifs in mammalian two-hybrid assays performed in HEK293 cells. 1 μM (2S)-DA is used. RLU is relative light unit that is normalized with β-galactosidase activity as transfection control.
AceDAF-12 binds to the coactivator peptide (SRC2-3) in a manner reminiscent of other activated nuclear receptors. Fig. 2E shows that helix H12 is in its active conformation and packed against helices H3–H5 to form a functional coactivator binding surface. Lys-504 from the C-terminal end of helix H3 and Glu-681 from the center of the AF2 helix form the charge clamp that anchors both ends of the SRC2-3 peptide by H-bonding. The locked SRC2-3 peptide adopts a two-turn clamp that anchors both ends of the SRC2-3 peptide by and Glu-681 from the center of the AF2 helix form the charge clamp that anchors both ends of the SRC2-3 peptide by H-bonding. The locked SRC2-3 peptide adopts a two-turn clamp that anchors both ends of the SRC2-3 peptide by H-bonding. The locked SRC2-3 peptide adopts a two-turn clamp that anchors both ends of the SRC2-3 peptide by H-bonding. The locked SRC2-3 peptide adopts a two-turn clamp that anchors both ends of the SRC2-3 peptide by H-bonding.

Comparison of AceDAF-12 and SstDAF-12 LBD Structures—
The DA complexes a and b have an overall architecture similar to the SstDAF-12 LBD (complexed with (25R)-Δ7-DA), revealed by superposition (both r.m.s.d.s = 1.13). The only noticeable difference is the ligand conformation, which is probably due to the opposite stereochemistry at the C25 position of ligands (see supplemental Fig. S3). With two DAF-12 LBD structures, we first investigated why DAF-12 has species-specific responses to DAs (14).

It was previously shown that mutation of key ligand-binding residues (R532M/R599M/R598M and Q571E/Q637E/Q638E) differentially affected DA binding in hookworm, threadworm, and C. elegans DAF-12 (14). Our AceDAF-12/(25S)-Δ7-DA structure reveals the molecular basis for these differences. At the C27-carboxyl end of Δ7-DA, Arg-536 of AceDAF-12 is pointed away from the carboxyl group due to charge repulsion by Arg-532 (Fig. 2D). We reasoned that exchange of Arg-532 with a noncharged methionine is likely to allow the Arg-536 side chain to swing back and to replace Arg-532 in binding the ligand carboxyl group (Fig. 2D). The amino acid corresponding to Arg-536 in SstDAF-12 is a valine (Val-603), which cannot compensate for a mutation of the Arg-532 analogous Sst Arg-599, making DA binding markedly more dependent on Sst Arg-599 than on Ace Arg-532. However, this compensation is impaired in AceDAF-12 R532K and CelDAF-12 R598K (14) because the mutated lysine repels the charge of the compensating arginine, thereby preventing its H-bonding to the ligand. We confirmed this mechanism by introducing a R536V mutation in AceDAF-12 R532M and a R602V mutation in CelDAF-12 R599M, both of which abolished ligand activation of DAF-12 (Fig. 3, A and C). In contrast, the reciprocal mutation of V603R in SstDAF-12 R599M recovered the receptor activity (Fig. 3B).

At the other end of Δ7-DA is an H-bonding network based on Arg-574, which interacts with Gln-571 and Glu-658, respectively (Fig. 2C). This network increases the tolerance of hookworm DAF-12 against mutation of Gln-571, which locks the C3-keto group of the ligand by H-bonding (Fig. 2C). Correspondingly, AceDAF-12 Q571E, but not CelDAF-12 Q571E or SstDAF-12 Q638E, can still be activated by Δ7-DA (14), because the H-bonding network hub Arg-574 still makes Glu an effective H-bond donor for the C3-keto group of Δ7-DA. The corresponding amino acids Gly-640 in SstDAF-12 and Lys-641 in CelDAF-12 cannot, or only weakly, form these H-bonding interactions. We confirmed this mechanism by introducing an R574G mutation into AceDAF-12 Q571E, which as expected abolished the response of the receptor to Δ7-DA stimulation. Moreover, introduction of R574K that weakens the H-bonding network, partially impaired receptor activity (Fig. 3A).

However, introduction of K641R into SstDAF-12 Q637E or G640R into CelDAF-12 Q638E did not rescue the receptor response to Δ7-DA (Fig. 3, B and C), suggesting the involvement of other structural elements in hookworm DAF-12s that assist in ligand binding. In addition, in both hookworm complexes a and b, a water molecule is located near either end of (25S)-Δ7-DA and H-bonds with the ligand, which is not seen in the SstDAF-12 LBD structure (Fig. 2, C and D).

Comparison of AceDAF-12 and FXR LBD Structures—Primary sequence analysis of full-length nuclear receptors suggested that DAF-12 is most similar to mammalian FXR, LXR, constitutively active receptor, pregnane X receptor, and vitamin D receptor. The LBD of DAF-12 is 33% identical to that of...
FXR, 29% to LXRβ, 26% to LXRα, 26% to constitutively active receptor, 25% to pregnane X receptor, and 23% to vitamin D receptor (5, 24). To understand the similarity between DAF-12 and mammalian nuclear receptors on a three-dimensional structural basis, we superposed the AceDAF-12 LBD complex a onto a number of mammalian nuclear receptor LBD-ligand complexes. DAF-12 shares a closer three-dimensional structural appearance to FXR, LXR, and vitamin D receptor as predicted by the primary sequence analysis (The calculated r.m.s.d. are summarized in supplemental Table S2). Interestingly, further inspection revealed that DAF-12 and FXR adopt the same ligand orientation that is different from other nuclear receptors (25). Their A ring of the steroid skeleton faces the back layer of the ligand binding pocket in both DAF-12 and FXR, and their D ring faces outward toward helix H1 (Fig. 4A), whereas all other known nuclear receptors (including LXR and vitamin D receptor) arrange their cognate steroid-based ligands in the opposite direction (26, 27). Furthermore, DAF-12 and FXR use conserved amino acids to interact with the carboxyl group of the ligand. The interaction of AceDAF-12 Arg-532 with the carboxyl group of Δ7-DA corresponds to the binding of FXR Arg-328 to the carboxyl group of its ligand 6α-ethyl-chenodeoxycholic acid (6ECDCA) (Fig. 4B). Although the amino acids are not conserved in binding the other end of the ligand, a similar H-bond interaction between Gln-571 and the C3-keto group of 6ECDCA (Fig. 4C) as seen in complex b. The three-dimensional structural similarity between DAF-12 and FXR indicates that they share common structural features in binding bile acid-like molecules and suggests that FXR is the closest DAF-12 ortholog among mammalian nuclear receptors.

**Activation of AceDAF-12 by Mammalian Bile Acid(-like) Metabolites**—DAs were identified in *C. elegans*, but so far they have not been detected in parasitic nematodes (1). Most parasitic nematodes constitutively enter iL3 and are unable to complete development outside their hosts, perhaps because of missing parts of the enzyme cascade that generates DAF-12 ligands (14). Consistently, the orthologs for DAF-9 (the key enzyme in *C. elegans* DA production) have not been characterized in parasitic nematodes. Also, the difference of EC_{50} values in DA activation of *C. elegans* and parasitic DAF-12s have their own distinct physiological ligands (14). The biosynthesis of bile acids and DAs has the same chemistry, and their binding to the receptors conserves the same structural mechanism. Therefore, we wanted to investigate what mammalian bile acid(-like) metabolites can activate the parasitic DAF-12s and be their potential host ligands.

Previous studies have showed that mammalian bile acid metabolites such as 3-keto LCA could activate *Cel*DAF-12 (1). In this study, we examined the effect of 3-keto LCA on parasitic DAF-12s from *S. stercoralis* and *A. caninum*. As shown in Fig. 5A, 3-keto LCA stimulated the activity of all the tested DAF-12s to a comparable level. However, 3-keto LCA is toxic at a higher concentration (28) and thus unlikely to be the host ligand.

Cholestenoic acid is a bile acid-like metabolite and circulates in human blood with concentrations between 300 and 500 nM (29). It is a potential product of 27-hydroxycholesterol by CYP27A1 action, whereas 27-hydroxycholesterol is a product of cholesterol by CYP27A1 action and serves as one of the bile acid precursors (3, 29). (25S)-Cholestenoic acid has been shown to weakly activate *Cel*DAF-12 and rescue the dauer formation in *daf-9* mutants (30). Therefore, we investigated the effect of this bile acid-like metabolite on the hookworm AceDAF-12 activation together with its (25R)-diastereomer. The cotransfection assay results indicated that AceDAF-12 was more sensitive to (25S)-cholestenoic acid (EC_{50} = 4 μM) than *Cel*DAF-12 (EC_{50} > 30 μM) (Fig. 5B), whereas *Cel*DAF-12 has the higher binding affinity to DAs than AceDAF-12 (14). The activities of both DAF-12s were not stimulated by (25R)-cholestenoic acid, suggesting the importance of stereochemistry at the C25 position as previously shown (1, 30).

**Structure of a Complex between the AceDAF-12 LBD with (25S)-Cholestenoic Acid**—To understand the molecular basis for DAF-12 activation by mammalian bile acid(-like) metabolites, we set out to solve the x-ray crystal structure of the AceDAF-12 LBD complexed with (25S)-cholestenoic acid. AlphaScreen interaction assays demonstrated that DAF-12s have a similar binding peptide profiling in the presence of cholestenoic acids relative to DAs (supplemental Fig. S4). Interest-
ingly, both (25S)- and (25R)-cholestenoic acids can bind DAF-12s in AlphaScreen assays, suggesting that, in vivo, the physiological context of endogenous coactivators plays an important role in dictating activity.

The structure was determined at a high resolution of 1.25 Å. The electron density map precisely illustrated the amino acids and waters involved in binding the ligand (supplemental Fig. S5). Comparison of this structure to the DA complex a or b by superposition indicated a very close overlapping of the three-dimensional architectures (both r.m.s.d. = 0.437). The only noticeable difference lies in the conformation of the ligands that are well overlapped except for their A and B rings (Fig. 5C). This is caused by the double bond position on their B rings and results in different H-bonding networks at the C3-end of ligands. Structure analysis explains the weaker binding of cholestenoic acid to AceDAF-12 relative to DA. First, the water molecule that forms H-bonds with the C3-end of the ligand in the (25S)-DA structures is not present in the cholestenoic acid structure (see Figs. 5C and 2C). Second, all the H-bonds that build up the C3-end network are weaker in the cholestenoic acid structure. Interestingly, the network hub Arg-574 forms H-bonds with Glu-570, instead of interacting with Glu-658 as seen in the DA structure. Because the corresponding arginine is absent in CelDAF-12 (Lys-641), a delicate H-bonding network that assists the ligand binding may not exist in CelDAF-12. Together, the configuration of the A and B rings is the major determinant of ligand potency, as the ligand binding pattern is similar at the C27-carboxylic end of both ligands (see Figs. 5C and 2D).

**DISCUSSION**

In this paper, we present high resolution structures of two DAF-12 complexes that represent the first hookworm nuclear receptor structures. Our analysis reveals the structural features for the species-specific responses of DAF-12. This work also contributes to our understanding of the biochemical principles that may have guided the convergent evolution of a unique parasite-host relationship. In *C. elegans* DAs work as key postprandial signals through the nuclear receptor DAF-12 to direct worm energy utilization. This pathway is reminiscent of the function of bile acids in mammals to direct postprandial nutrient energy homeostasis through the nuclear receptor FXR (31). Indeed, the biochemistry of the DA-DAF-12 endocrine signaling pathway shares a remarkable similarity to that of the bile acid-FXR signaling pathway (Fig. 6). DA and bile acids are chemically similar steroid hormones that are synthesized by orthologous cytochrome P450 enzymes (DAF-9 and CYP27A1), and as shown in this study, DA and bile acids bind in a similar fashion to orthologous nuclear receptors (DAF-12 and FXR). Importantly, the DAF-12 pathway is also conserved in parasitic species (14, 15), with the intriguing exception that no parasite homologs of DAF-9 have been characterized to date. These findings imply that parasitic nematodes, unlike free-living *C. elegans*, may lack the ability to produce their own DAF-12
Hookworm DAF-12 Structures

![Diagram of bile acid-like signaling pathways in nematodes and mammals.](image)

**FIGURE 6. Model of conserved bile acid-like signaling pathways in nematodes and mammals.** Bile acid-like signaling pathways in mammals and nematodes are compared and illustrated. Free-living nematodes (e.g. *C. elegans*) produce their own DAF-12 ligands to regulate the reproductive development. Parasitic nematode (e.g. hookworms) might use the host bile acid-like metabolites to activate their DAF-12 to regulate the reproductive development.

**REFERENCES**


**Acknowledgments**—We thank Zhu Wang and Nathaniel Schaffer for reading the manuscript. We also thank Z. Wawrzak and J. S. Brunzelle for assistance in data collection at the beamlines of sector 21 (Life Sciences Collaborative Access Team). The photon service is funded in part by the Michigan Economic Development Corp. and the Michigan Technology Tri-Corridor Grant 088P1000817. Use of the Advanced Photon Source was supported by the Office of Science of the United States Department of Energy.


